When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
暂无分享,去创建一个
H. Pass | C. Goparaju | K. O'Byrne | G. Reid | D. Fennell | L. Mutti | B. Murer | D. Nonaka | K. Griggs | M. Kirschner | S. Klebe | B. Stanfill | A. Byrne | S. Gray | S. Raeppel | A. Soltermann | A. Baird | S. Finn | S. Cuffe | M. Barr | D. Easty | I. Opitz | D. O'Donnell | M. Jarzabek | L. Shiels | Chengguang Wu | L. MacDonagh
[1] K. S. Dalal,et al. Oncology drugs. , 2019, Nursing.
[2] E. Felley-Bosco. Special Issue on Mechanisms of Mesothelioma Heterogeneity: Highlights and Open Questions , 2018, International journal of molecular sciences.
[3] Z. Zeng,et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities , 2018, Molecular Cancer.
[4] M. Grilli,et al. l-Acetylcarnitine: A Mechanistically Distinctive and Potentially Rapid-Acting Antidepressant Drug , 2017, International journal of molecular sciences.
[5] A. Califano,et al. Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response* , 2017, Molecular & Cellular Proteomics.
[6] Daniel F Gilbert,et al. Cell Viability Assays , 2016, Methods in Molecular Biology.
[7] A. Ullrich,et al. Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo , 2016, Oncotarget.
[8] Eric Therrien,et al. Design, synthesis and RON receptor tyrosine kinase inhibitory activity of new head groups analogs of LCRF-0004. , 2015, Bioorganic & medicinal chemistry letters.
[9] Eric Therrien,et al. Design and synthesis of constrained analogs of LCRF-0004 as potent RON tyrosine kinase inhibitors. , 2015, Bioorganic & medicinal chemistry letters.
[10] Eric Therrien,et al. Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor. , 2015, Bioorganic & medicinal chemistry letters.
[11] W. Sellers,et al. Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure , 2015, EMBO reports.
[12] J. Freeman,et al. Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets , 2015, Oncotarget.
[13] Robert Williams. Discontinued in 2013: oncology drugs , 2015, Expert opinion on investigational drugs.
[14] Chirayu Pankaj Goswami,et al. PROGgeneV2: enhancements on the existing database , 2014, BMC Cancer.
[15] T. Golub,et al. Genetic modifiers of EGFR dependence in non-small cell lung cancer , 2014, Proceedings of the National Academy of Sciences.
[16] Kenichi Suda,et al. The insulin‐like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild‐type epidermal growth factor receptor , 2014, International journal of cancer.
[17] E. Haura,et al. Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer , 2014, Clinical Cancer Research.
[18] J. Fletcher,et al. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma , 2014, British Journal of Cancer.
[19] C Goparaju,et al. Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation , 2014, Cell Death and Disease.
[20] R. Salgia,et al. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. , 2014, Cancer research.
[21] A. Welm,et al. The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming , 2014, Cell reports.
[22] G. Lemke. Biology of the TAM receptors. , 2013, Cold Spring Harbor perspectives in biology.
[23] S. Zhao,et al. Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines , 2013, Oncogenesis.
[24] E. Cuyás,et al. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations , 2013, Scientific Reports.
[25] M. Brattain,et al. Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi) , 2013, PloS one.
[26] Ruiwen Zhang,et al. MSP–RON signalling in cancer: pathogenesis and therapeutic potential , 2013, Nature Reviews Cancer.
[27] V. Vaira,et al. The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma , 2013, British Journal of Cancer.
[28] J. Graff,et al. LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models , 2012, Investigational New Drugs.
[29] Andrea I. McClatchey,et al. Spatial regulation of receptor tyrosine kinases in development and cancer , 2012, Nature Reviews Cancer.
[30] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[31] N. Le Stang,et al. Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma: A Series of 157 Cases from the MESOPATH Group , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[32] Yao Dai,et al. Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation , 2012, Clinical & Experimental Metastasis.
[33] L. Trusolino,et al. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils , 2011, EMBO molecular medicine.
[34] K. Kashima,et al. Tyrosine kinase receptor RON and its ligand MSP in Merkel cell carcinoma. , 2011, Pathology, research and practice.
[35] Peter T. Yu,et al. IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration. , 2011, Carcinogenesis.
[36] Ruiwen Zhang,et al. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells , 2011, Molecular Cancer.
[37] Y. Bang,et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma , 2011, Cancer biology & therapy.
[38] L. Neumayer,et al. Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase. , 2011, Genes & cancer.
[39] A. Olshen,et al. Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[40] J. Fletcher,et al. AXL regulates mesothelioma proliferation and invasiveness , 2011, Oncogene.
[41] P. Comoglio,et al. Ron kinase transphosphorylation sustains MET oncogene addiction. , 2011, Cancer research.
[42] D. Henderson,et al. Validation of tissue microarray technology in malignant pleural mesothelioma , 2011, Pathology.
[43] Tsun-Jen Cheng,et al. Global Magnitude of Reported and Unreported Mesothelioma , 2011, Environmental health perspectives.
[44] A. Darnton,et al. Projection of mesothelioma mortality in Britain using Bayesian methods , 2010, British Journal of Cancer.
[45] C. Maroun,et al. Identification of a novel series of potent RON receptor tyrosine kinase inhibitors. , 2010, Bioorganic & medicinal chemistry letters.
[46] R. Stahel,et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[47] H. Moch,et al. Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[48] Y. Yatabe,et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. , 2009, Carcinogenesis.
[49] J. Fargnoli,et al. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. , 2009, Journal of medicinal chemistry.
[50] T. Barrette,et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. , 2007, Neoplasia.
[51] K. O'Byrne,et al. EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. , 2006, Lung cancer.
[52] Michael R Green,et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. , 2005, Molecular cell.
[53] Deborah Imel Nelson,et al. The global burden of disease due to occupational carcinogens. , 2005, American journal of industrial medicine.
[54] A. Musk,et al. Malignant mesothelioma , 2005, The Lancet.
[55] P. Herrlich,et al. A five-amino-acid peptide blocks Met- and Ron-dependent cell migration. , 2005, Cancer research.
[56] David J Sugarbaker,et al. Tumorigenesis and Neoplastic Progression Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling , 2005 .
[57] P. Comoglio,et al. Truncated RON Tyrosine Kinase Drives Tumor Cell Progression and Abrogates Cell-Cell Adhesion Through E-Cadherin Transcriptional Repression , 2004, Cancer Research.
[58] B. Peace,et al. Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor. , 2003, Experimental cell research.
[59] Ming-Hai Wang,et al. Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. , 2003, Carcinogenesis.
[60] Claude Denham,et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] M. Lerman,et al. Gene structure of the human receptor tyrosine kinase RON and mutation analysis in lung cancer samples , 2000, Genes, chromosomes & cancer.
[62] M. Stella,et al. Cross-talk between the proto-oncogenes Met and Ron , 2000, Oncogene.
[63] D. Witte,et al. The Ron/STK receptor tyrosine kinase is essential for peri-implantation development in the mouse. , 1999, The Journal of clinical investigation.
[64] A. Simeone,et al. The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. , 1995, Oncogene.
[65] J. Peto,et al. Continuing increase in mesothelioma mortality in Britain , 1995, The Lancet.
[66] L. Naldini,et al. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. , 1994, The EMBO journal.
[67] J. Wagner,et al. Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province , 1960, British journal of industrial medicine.
[68] Mariette DiChristina,et al. Promises and Perils. , 2015 .
[69] P. V. Van Schil,et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[70] G. Scambia,et al. RON and cisplatin resistance in ovarian cancer cell lines. , 2010, Oncology research.
[71] G. Gordon,et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. , 2006, Cancer research.